Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.41 |
| ▸ | TNKS | O95271 | 1/20 | 0.41 |
| ▸ | GABRP | O00591 | 4/20 | 0.40 |
| ▸ | GABRD | O14764 | 4/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.40 |
| ▸ | GABRB1 | P18505 | 4/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.40 |
| ▸ | GABRA3 | P34903 | 4/20 | 0.40 |
| ▸ | GABRA2 | P47869 | 4/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.40 |
| ▸ | GABRA4 | P48169 | 4/20 | 0.40 |
| ▸ | GABRE | P78334 | 4/20 | 0.40 |
| ▸ | GABRA6 | Q16445 | 4/20 | 0.40 |
| ▸ | GABRG1 | Q8N1C3 | 4/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8679 | 0.89 | GABRP (0.55) | NPC1HPGDRAB9ASMN1; SMN2NMUR2 | |
| SCHEMBL8732 | 0.88 | NMUR2 (0.54) | NPC1HPGDRAB9ASMN1; SMN2NMUR2 | |
| SCHEMBL8545 | 0.85 | GABRP (0.41) | NPC1HPGDRAB9ASMN1; SMN2NMUR2 | |
| SCHEMBL8910 | 0.84 | TNKS (0.52) | TNKSGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL8856 | 0.80 | GABRA1 (0.53) | NPC1RAB9ATNKSGABRPGABRD | |
| SCHEMBL13717629 | 0.80 | NMUR2 (0.40) | NPC1HPGDRAB9ASMN1; SMN2NMUR2 | |
| SCHEMBL8059 | 0.79 | GABRP (0.53) | NPC1HPGDRAB9ASMN1; SMN2NMUR2 | |
| SCHEMBL8360 | 0.77 | NMUR2 (0.51) | NPC1HPGDRAB9ASMN1; SMN2NMUR2 | |
| SCHEMBL8047 | 0.77 | GABRP (0.56) | NPC1HPGDRAB9ASMN1; SMN2NMUR2 | |
| SCHEMBL8544 | 0.77 | PIK3CD (0.42) | NPC1HPGDRAB9ASMN1; SMN2NMUR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200239427-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS AG (CH) | 2020-07-30 | — | — | US | claimed |
| EP-3444242-A2 | NOVEL BENZOPYRAN KINASE MODULATORS | Rhizen Pharmaceuticals S.A. (CH) | 2019-02-20 | — | — | EP | claimed |
| EP-3050876-A2 | KINASE MODULATORS | Rhizen Pharmaceuticals S.A. (CH) | 2016-08-03 | — | — | EP | claimed |
| EP-2496567-A2 | NOVEL BENZOPYRAN KINASE MODULATORS | Rhizen Pharmaceuticals S.A. (CH) | 2012-09-12 | — | — | EP | claimed |
| US-20110118257-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS SA (CH) | 2011-05-19 | — | — | US | claimed |
| WO-2011055215-A2 | NOVEL KINASE MODULATORS | INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2011-05-12 | — | — | WO | claimed |
| US-20240360095-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS AG (CH) | 2024-10-31 | — | — | US | disclosed |
| US-11858907-B2 | Kinase modulators | RHIZEN PHARMACEUTICALS AG (CH) | 2024-01-02 | — | — | US | disclosed |
| US-20200239427-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS AG (CH) | 2020-07-30 | — | — | US | disclosed |
| US-10442783-B2 | 2,3-disubstituted chromen-4-one compounds as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2019-10-15 | — | — | US | disclosed |
| EP-3444242-A2 | NOVEL BENZOPYRAN KINASE MODULATORS | Rhizen Pharmaceuticals S.A. (CH) | 2019-02-20 | — | — | EP | disclosed |
| EP-2496567-B1 | NOVEL BENZOPYRAN KINASE MODULATORS | RHIZEN PHARMACEUTICALS S A (CH) | 2017-07-12 | — | — | EP | disclosed |
| US-20160318890-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS AG (CH) | 2016-11-03 | — | — | US | disclosed |
| US-9018375-B2 | Substituted chromenes as kinase modulators | RHIZEN PHARMACEUTICALS SA (CH) | 2015-04-28 | — | — | US | disclosed |
| US-20140080827-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS SA (CH) | 2014-03-20 | — | — | US | disclosed |
| US-8642607-B2 | 4H-chromen-4-one compounds as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2014-02-04 | — | — | US | disclosed |
| EP-2496567-A2 | NOVEL BENZOPYRAN KINASE MODULATORS | Rhizen Pharmaceuticals S.A. (CH) | 2012-09-12 | — | — | EP | disclosed |
| US-20120059001-A1 | NOVEL KINASE MODULATORS | INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2012-03-08 | — | — | US | disclosed |
| US-20110118257-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS SA (CH) | 2011-05-19 | — | — | US | disclosed |
| WO-2011055215-A2 | NOVEL KINASE MODULATORS | INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10442783-B2 | 2,3-disubstituted chromen-4-one compounds as modulators of protein kinases | PIK3CB, PIK3CD, PDPK1 | NPC1 1387/4885HPGD 2895/4885RAB9A 1413/4885 |
| US-20240360095-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | NPC1 1419/4885HPGD 2910/4885RAB9A 1297/4885 |
| US-20140080827-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | NPC1 1419/4885HPGD 2910/4885RAB9A 1297/4885 |
| US-20110118257-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | NPC1 1419/4885HPGD 2910/4885RAB9A 1297/4885 |
| US-20200239427-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | NPC1 1419/4885HPGD 2910/4885RAB9A 1297/4885 |
| US-11858907-B2 | Kinase modulators | RPS6KA1, RPS6KA2, PRKAR2A | NPC1 2061/4885HPGD 1641/4885RAB9A 1518/4885 |
| US-20160318890-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | NPC1 1419/4885HPGD 2910/4885RAB9A 1297/4885 |
| US-20120059001-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | NPC1 1419/4885HPGD 2910/4885RAB9A 1297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.